Abingworth LLP - 06 Oct 2021 Form 4 Insider Report for eFFECTOR Therapeutics, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 06 Oct 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Dec 2021, 15:30:28 UTC
Prior SEC filing: 01 Oct 2021
Next SEC filing: 05 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ John Heard

Key filing fact

Abingworth LLP filed Form 4 for eFFECTOR Therapeutics, Inc. on 17 Dec 2021.

Key facts

This page summarizes Abingworth LLP's Form 4 filing for eFFECTOR Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Dec 2021, 15:30.

Change

Previous filing in this sequence was filed on 01 Oct 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EFTR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 06 Oct 2021
Ownership: See Footnotes
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $11.36
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VI, LP ("ABV VI"). Abingworth General Partner VI LLP serves as the general partner of Abingworth GP. ABV VI (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VI.

Footnote F2

The option (the "Option") was granted to Brian Gallagher ("Gallagher"), a director of the Issuer and a member of the investment committee of ABV VI (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VI. The Option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Gallagher's continued service with the Issuer through each vesting date. Under an agreement between Gallagher and the Reporting Person, Gallagher is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of the Reporting Person.

Footnote F3

ABV VI may be deemed the indirect beneficial owner of the Option, and Gallagher may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. Each of ABV VI, Abingworth GP, Abingworth General Partner VI LLP, Gallagher, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.